P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) has issued last April its earnings report for the first quarter.
On Monday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed its financial results for the second quarter.
P.A.M. Transportation Services Q1 Financial Highlights
For the period, P.A.M. Transportation Services had a net income of $2.93 million, which is equivalent to a diluted earnings per share (EPS) of $0.41. This shows a significant decline from the same quarter last year, during which the company has a net income of $5.37 million or a diluted EPS of $0.72.
P.A.M. Transportation Services had a total operating revenue of $103.59 million during the first quarter, which is up by more than 13% from the $99.48 million operating revenue during the same period last year.
According to Daniel Cushman, P.A.M. Transportation Services President, the year-over-year revenue growth can be largely attributed to the increase in the company’s total fleet size. The strong performance in the company’s Dedicated and Mexico segments also contributed to the revenue growth seen during the first quarter.
However, operating costs also significantly surged as expenses involving driver acquisition, fuel, and healthcare rose year-over-year. Net driver acquisition costs alone soared by about $1.40 million year-over-year. Meanwhile, net fuel costs for the period jumped by about $1.20 million from the same period in 2015. Lastly, healthcare costs posted a year-over-year increase of $1 million.
While the quarterly figures came in somewhat disappointing, it is still nonetheless considered as one of the company’s best-performing first quarters in history.
Gilead Sciences Q2 Financial Highlights
For the second quarter, Gilead Sciences had a net income of $3.50 billion, which is equivalent to a diluted EPS of $2.58. This is significantly lower than the net income of $4.50 billion or a diluted EPS of $2.92 reported during the same period last year.
The California-based company had a total revenue of $7.80 billion, which is relatively down from the $8.20 billion revenue posted during the same quarter in 2015.
In terms of segmental performance worldwide for the second quarter, Product Sales had brought in $7.70 billion, which is down from last year’s $8.10 billion; Antiviral Product Sales had brought in $7.10 billion, which is down from last year’s $7.60 billion; and Other Product Sales had brought in $525 million, which is up from last year’s $495 million.
On the other hand, the pharmaceutical giant’s operating expenses also rose significantly year-over-year. Research and Development (R&D) costs jumped to a whopping $1.48 billion from $818 million while Selling, General, and Administrative (SG&A) costs increased to $890 million from $812 million.
Gilead Sciences also revealed on Monday a quarterly dividend of $0.47 per share. Shareholders of record on September 16 will receive the third quarter dividend on September 29.
